Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyMaryland Physicians Care Allergen Coverage | OpenP…
    Ask Trek AI about this page
    CurrentMaryland Physicians CarePolicy EVH_MP_2503.MPC

    Allergen Immunotherapy

    Customize your policy alerts

    Sign up for marylandphysicianscarempc Policy EVH_MP_2503.MPC alerts

    Get alerted when Policy EVH_MP_2503.MPC changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of allergen immunotherapy, including subcutaneous allergy injections, venom immunotherapy, allergen extract preparation, and rapid desensitization for Maryland Physicians Care members and providers.

    Policy Summary
    PayerMaryland Physicians Care
    PolicyAllergen Immunotherapy
    Policy CodePolicy EVH_MP_2503.MPC
    Change TypeAnnual review with revised indications, limitations, and procedure code descriptions
    Effective DateSep 1, 2026
    Last ReviewAug 20, 2026
    Next Review DateN/A
    Key ActionDocument IgE-mediated hypersensitivity demonstrated by appropriate skin testing or serology/in vitro testing.
    SourceLink
    POLICY UPDATE CHANGES

    The annual review revised the description of the service, indications, limitations, and descriptions of several allergen immunotherapy procedure codes.

    11Applicable procedure codes
    POS 11, 22Covered places of service
    POS 12

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Home setting excluded
    ≥5 yearsMinimum asthma age
    ≥30 IU/mLAsthma pathway IgE threshold
    ≥2 or ≥1 hospitalization/EDAsthma exacerbation threshold

    Covered and Non-Covered Indications

    Covered indications

    Allergen immunotherapy (AIT) is covered for the following indications when there is evidence of an immunoglobulin E (IgE)-mediated antibody to a potent extract of the antigen from a skin test or serology.

    ALL of the following

    • Evidence of an IgE-mediated antibody to a potent extract of the antigen demonstrated by skin test or serology.
    • ONE of the following covered indications

      • Allergic rhinitis (AR): ALL of the following

        • Perennial, seasonal (including conjunctivitis), or mold-induced allergic rhinitis.
        • Continued symptoms of allergic rhinitis after natural exposure to an allergen, with symptoms significantly impacting activities of daily living (ADLs), even after allergen avoidance and/or pharmacologic (drug) therapy.
      • Hymenoptera sensitivity (venom immunotherapy [VIT]): ALL of the following

        • Sensitivity to Hymenoptera (bees, wasps, or ants).
        • Life-threatening reaction(s) to Hymenoptera insect stings: ONE of the following

          • Systemic reaction.
          • Cutaneous reaction: ALL of the following

            • ONE of the following associated symptoms

              • Respiratory symptoms, including laryngeal edema or bronchospasm.
              • Cardiovascular symptoms, including hypotension or shock.
      • Allergic (extrinsic) asthma: ONE of the following

        • Uncontrolled moderate-to-severe asthma in members ≥ 5 years of age who previously received therapy with a humanized monoclonal antibody directed

          The source excerpt ends after “directed”; no additional asthma criterion was provided.

    Special consideration, including assessment of risks and benefits, should be given for members who are younger than 5 years or elderly, pregnant women, or members with immunodeficiency syndromes, autoimmune diseases, or malignant disease. AIT is usually not initiated during pregnancy.

    AIT is not covered for treatment of food allergy, migraine headaches, nonallergic vasomotor rhinitis, intrinsic (nonallergic) asthma, chronic urticaria, atopic dermatitis, or angioedema.

    AIT is covered only when performed in Place of Service (POS) 11 (Medical Office Visit) or POS 22 (On Campus-Outpatient Hospital). AIT performed in the home setting (POS 12) is considered experimental and investigational and is not covered.

    AIT is not covered when provided by providers other than board-certified allergists, asthma-treating pulmonologists, or board-certified ear, nose, and throat (ENT) physicians.

    The following are not evidence-based forms of AIT and are not covered: acupuncture; allergoids (allergens chemically modified for immunotherapy by lessening the immune response); detoxification; enzyme potentiated desensitization (EDP); homeopathy; photo-inactivated extracts; polymerized extracts; poison ivy/oak extracts for immunotherapy to prevent Toxicodendron (Rhus) dermatitis; intravenous vitamin therapy; and low-dose desensitization.

    Applicable Codes and Eligibility Thresholds

    Covered CPT CodesCPTCovered
    95115Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection.
    95117Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections.
    95144Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single dose vial(s) (specify number of vials).
    95145Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); single stinging insect venom.
    95146Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 2 single stinging insect venoms.
    95147Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 3 single stinging insect venoms.
    95148Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 4 single stinging insect venoms.
    95149Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 5 single stinging insect venoms.
    95165Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses).
    95170Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; whole body extract of biting insect or other arthropod (specify number of doses).
    1–10 of 11
    1/2
    Age for Covered Allergic Asthma
    Minimum age≥ 5 years
    Applicable conditionUncontrolled moderate-to-severe allergic (extrinsic) asthma
    Eligibility contextApplies to covered asthma pathways for members aged 5 years or older
    Pretreatment IgE for Allergic Asthma
    Minimum pretreatment IgE≥ 30 IU/mL
    Applicable conditionUncontrolled moderate-to-severe allergic asthma
    Additional testing

    Documentation and Denial-Risk Requirements

    Documentation Required

    Failure of Avoidance or Medication Therapy

    Document persistent symptoms of allergic rhinitis after natural allergen exposure that significantly affect activities of daily living despite allergen avoidance and/or pharmacologic (drug) therapy.

    • Symptoms continue after natural exposure to the relevant allergen.
    • Symptoms significantly impact activities of daily living.
    • Document unsuccessful allergen avoidance and/or pharmacologic therapy.
    Documentation Required

    Prior IL-5 Monoclonal Antibody Therapy

    For the applicable allergic asthma pathway, document that the member is at least 5 years of age and has uncontrolled moderate-to-severe asthma despite prior treatment with a qualifying humanized monoclonal antibody directed against interleukin-5 (IL-5) for severe persistent asthma within the past year.

    • Prior IL-5-directed humanized monoclonal antibody therapy must be documented.
    • The qualifying therapy must have been received within the past year.

    Allergen Immunotherapy Overview

    Allergen immunotherapy, also called desensitization, hyposensitization, allergy injection therapy, or allergy shots, is used to reduce sensitivity to identified allergens. Treatment begins with low doses that are gradually increased until a maintenance dose is reached; maintenance injections may be given every two to six weeks and treatment may continue for several years.

    Key Terms

    Subcutaneous Allergen Immunotherapy (AIT)
    AdministrationAllergen immunotherapy administered by injection under the skin
    Also calledDesensitization, hyposensitization, allergy injection therapy, or allergy shots
    Treatment approachDoses begin low and are gradually increased until the member becomes tolerant of the allergen
    Venom Immunotherapy (VIT)
    PurposeImmunotherapy for sensitivity to Hymenoptera insect venom
    Included insectsBees, wasps, and ants
    Qualifying reaction
    Policy Summary
    PayerMaryland Physicians Care
    PolicyAllergen Immunotherapy
    Policy CodePolicy EVH_MP_2503.MPC
    Change TypeAnnual review with revised indications, limitations, and procedure code descriptions
    Effective DateSep 1, 2026
    Last ReviewAug 20, 2026
    Next Review DateN/A
    Key ActionDocument IgE-mediated hypersensitivity demonstrated by appropriate skin testing or serology/in vitro testing.
    SourceLink
    On This Page
    Covered and Non-Covered IndicationsApplicable Codes and Eligibility ThresholdsDocumentation and Denial-Risk RequirementsAllergen Immunotherapy OverviewKey Terms
    Positive skin test or in vitro reactivity to at least 1 perennial aeroallergen
    Asthma Exacerbation History
    Steroid-treated exacerbations≥ 2 exacerbations requiring oral or injectable corticosteroid treatment in the last year
    Hospitalization or emergency care≥ 1 exacerbation resulting in hospitalization or an emergency medical care visit in the last year
    Poor symptom controlExamples include frequent symptoms or reliever use, activity limitation, or night waking
    Documentation Required

    Optimized Asthma Controller Therapy

    For the non-IL-5 pathway, document inadequate asthma control despite current treatment at optimized doses with both a medium-to-high dose inhaled corticosteroid and an additional asthma controller medication.

    • Medium-to-high dose inhaled corticosteroid.
    • Additional controller such as a long-acting beta2-agonist, long-acting muscarinic antagonist, leukotriene modifier, or sustained-release bronchodilator.
    • Document continued maintenance asthma treatment when used with monoclonal antibody therapy targeting IL-5 receptors.
    Documentation Required

    Allergen Testing Required

    Document IgE-mediated hypersensitivity to a potent antigen extract using appropriate skin testing or serology/in vitro testing.

    • Record the relevant positive skin test or serology/in vitro result.
    • For the asthma pathway, document positive skin testing or in vitro reactivity to at least one perennial aeroallergen.
    Documentation Required

    Allergic Rhinitis Documentation

    Document a qualifying allergic rhinitis diagnosis and ongoing symptoms after natural allergen exposure, including the effect on daily functioning.

    • Qualifying rhinitis includes perennial, seasonal (including conjunctivitis), or mold-induced allergic rhinitis.
    • Symptoms must continue after natural exposure and significantly impact activities of daily living.
    • Document the effect of symptoms and the failure of allergen avoidance and/or pharmacologic therapy.
    Documentation Required

    Venom Reaction Documentation

    For venom immunotherapy, document sensitivity to Hymenoptera insects and a qualifying life-threatening sting reaction.

    • Qualifying insects include bees, wasps, and ants.
    • The reaction must be systemic, or cutaneous with respiratory symptoms such as laryngeal edema or bronchospasm, or cardiovascular symptoms such as hypotension or shock.
    • Document the associated symptoms and clinical severity.
    Documentation Required

    Asthma Eligibility Documentation

    For allergic (extrinsic) asthma, document the member's age, qualifying allergen testing, pretreatment IgE when applicable, evidence of uncontrolled asthma, and required treatment history.

    • Member must be at least 5 years of age for the specified moderate-to-severe asthma pathways.
    • For the applicable pathway, document pretreatment IgE of at least 30 IU/mL and positive skin test or in vitro reactivity to at least one perennial aeroallergen.
    • Document at least one event in the last year: two or more exacerbations requiring oral or injectable corticosteroids; an exacerbation resulting in hospitalization or emergency medical care; or poor symptom control such as frequent symptoms or reliever use, activity limitation, or night waking.
    • Document inadequate control despite optimized medium-to-high dose inhaled corticosteroid plus an additional asthma controller, or prior qualifying IL-5 monoclonal antibody therapy as applicable.
    Denial Risk

    Excluded Conditions

    AIT is not covered for diagnoses or indications outside the policy's qualifying allergic rhinitis, Hymenoptera venom, and allergic asthma pathways.

    • Food allergy
    • Migraine headaches
    • Nonallergic vasomotor rhinitis
    • Intrinsic (nonallergic) asthma
    • Chronic urticaria or atopic dermatitis
    • Angioedema
    Billing Rule

    Uncovered Place of Service

    AIT is covered only in Place of Service (POS) 11 or POS 22. Treatment provided in the home setting, POS 12, is considered experimental and investigational and is not covered.

    • POS 11: Medical Office Visit — covered.
    • POS 22: On-Campus-Outpatient Hospital — covered.
    • POS 12: Home setting — experimental and investigational; not covered.
    Denial Risk

    Provider Qualification Requirement

    Covered AIT must be performed by an appropriately qualified provider: a board-certified allergist, an asthma-treating pulmonologist, or a board-certified ear, nose, and throat (ENT) physician.

    • Board-certified allergists
    • Asthma-treating pulmonologists
    • Board-certified ear, nose, and throat (ENT) physicians
    Denial Risk

    Non-Evidence-Based Treatments Excluded

    The following are not evidence-based forms of AIT and are not covered under this policy.

    • Acupuncture
    • Allergoids
    • Detoxification
    • Enzyme potentiated desensitization (EDP)
    • Homeopathy
    • Photo-inactivated extracts
    • Polymerized extracts
    • Poison ivy/oak extracts for prevention of Toxicodendron (Rhus) dermatitis
    • Intravenous vitamin therapy
    • Low-dose desensitization
    Note

    Higher-Risk Populations

    Apply individualized risk-benefit consideration before initiating or continuing AIT in higher-risk populations. AIT is usually not initiated during pregnancy, and special consideration is also required for young or elderly members and members with certain comorbidities.

    • Members younger than 5 years or elderly members
    • Pregnant members — AIT is usually not initiated
    • Members with immunodeficiency syndromes
    • Members with autoimmune diseases
    • Members with malignant disease
    Life-threatening reaction to Hymenoptera insect stings, either systemic or cutaneous with respiratory or cardiovascular symptoms
    IgE-Mediated Hypersensitivity
    DefinitionAn antibody-mediated allergic response involving immunoglobulin E (IgE)
    EvidenceDemonstrated by a skin test or serology
    Antigen contextThe response is directed to a potent extract of the antigen